MDx

Revenues in PerkinElmer's diagnostics business rose 23 percent in Q4, thanks largely to its acquisition of autoimmune diagnostic testing firm Euroimmun.

Israeli bioinformatics startup KolGene eventually wants to offer an end-to-end tool that's integrated with EHRs and LIMS.

The firm said it expects fourth quarter revenues of $12.3 million to $12.5 million, a year-over-year increase of 13 percent to 15 percent.

The firm said it completed approximately 176,000 Cologuard tests during the quarter, a 115 percent year-over-year spike.

The firm's blood-based Epi proLung lung cancer test looks for a combination of DNA methylation biomarkers.

Under the terms of the five-year deal, pharmaceutical company Ferrer will sell SelectMDx test directly to urologists in Spain.

Though revenues from its non-invasive heart transplant rejection test AlloMap fell about 5 percent, CareDx is already being reimbursed by Medicare for its new AlloSure test.

Excluding revenues from the sale of MDxHealth's colorectal cancer patents to Exact Sciences, total revenues increased approximately 3 percent for the period.

The company, which beat analyst estimates on both the top and bottom lines, said Cologuard test volume in Q3 2017 rose 136 percent year over year.

The firm, which said last week it expected to raise $15.9 million, has said it will use the net proceeds for working capital and general corporate purposes.

Pages